{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"91.6"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"groups":[{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg orally \\[PO\\] on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nLenalidomide: 25 mg PO on Days 1 through 14 of a 3-week cycle for 8 cycles, then stop.","id":"OG000","title":"V-DR"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1 and 8 of a 3-week cycle for 8 cycles, then stop.\n\nLenalidomide: 15 mg PO on Days 1 through 14 of a 3-week cycle for 8 cycles, then stop.","id":"OG001","title":"VDCR"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg orally PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1 and 8 of a 3-week cycle for 8 cycles, then stop.","id":"OG002","title":"V-DC"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.","id":"OG003","title":"VDC-mod"}],"paramType":"NUMBER","populationDescription":"The modified intent-to-treat population is defined as phase 2 patients received at least one dose of any drug.","reportingStatus":"POSTED","timeFrame":"survival probability at 1 year after randomization","title":"Probability of 1-year Survival","type":"SECONDARY","unitOfMeasure":"percentage of patients"}